Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Senores Pharmaceuticals Ltd. ( (IN:SENORES) ) has issued an announcement.
Senores Pharmaceuticals, Inc. has announced the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which will be marketed by Dr. Reddy’s Laboratories Inc. in the US market. This launch represents a strategic move for Senores as it enters a niche, under-penetrated market with significant sales potential, reflecting the company’s focus on serving unmet healthcare needs. The product is bioequivalent to Ferriprox Tablets and had U.S. sales of approximately $70 million for the twelve months ending in October 2025.
More about Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company that develops and manufactures a wide range of pharmaceutical products for the US, Canada, and other regulated and emerging markets. The company focuses on various therapeutic areas and dosage forms, with a portfolio that includes 46 ANDAs and 133 strengths, and a pipeline of 22 ANDAs and 52 strengths. Senores also engages in the development of complex generics and critical care injectables, with manufacturing facilities in the US and India.
Average Trading Volume: 13,142
Technical Sentiment Signal: Strong Buy
Current Market Cap: 35.56B INR
Learn more about SENORES stock on TipRanks’ Stock Analysis page.